CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data ...

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently ...

CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering firm whose stock has declined over 71% in the past year according to InvestingPro data, today announced the ...

Investing.com -- Shares of Vor Biopharma (NASDAQ:VOR) tumbled 68.1% following the company’s announcement of a strategic review and the winding down of its clinical and manufacturing operations. The ...